The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Corbus Pharmaceuticals Announces New Patent Issuance

02-Nov-2017 | Source : Corbus Pharmaceuticals | Visits : 4425
NORWOOD, MA - Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced in a press release  that the US Patent and Trademark Office ("USPTO") issued US Patent No. 9,801,849 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum, Corbus' lead product in development for the treatment of inflammatory diseases. The patent provides intellectual property protection for Corbus' use of anabasum to treat inflammatory diseases in the United States through 2034.

The patent is part of an expanding and comprehensive portfolio of patent applications and other intellectual property addressing the synthesis, manufacturing, formulation and uses of anabasum for a variety of indications including the Company's lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Anabasum is a synthetic oral endocannabinoid-mimetic drug candidate designed to resolve chronic inflammation and fibrotic processes through the activation of the cannabinoid receptor Type 2 ("CB2").

Mark Tepper, President and Chief Scientific Officer of Corbus, stated, "The issuance of this patent is significant in that it reinforces our intellectual property strategy based on the unique properties of anabasum to activate CB2 leading to the production of Specialized Pro-resolving lipid Mediators. This issued patent, in conjunction with the potential issuance of other multiple patent applications currently under review worldwide, provides Corbus with intellectual property rights to anabasum to 2034."

Yuval Cohen, PhD, CEO of Corbus, added, "The expansion of our intellectual property portfolio is an integral aspect of Corbus' clinical development and commercialization strategy aimed at positioning anabasum as a first-in-class therapy targeting multiple rare inflammatory-fibrotic diseases with clear unmet needs and significant morbidity and mortality. With recently generated positive clinical data in Phase 2 studies in systemic sclerosis, cystic fibrosis and dermatomyositis, anabasum is now targeting four indications with a combined patient population of over 500,000 in the US and EU." 

Related Articles